Roche’s Vabysmo Prefilled Syringe Receives the US FDA’s Approval for Vision Loss
Shots:
- The US FDA has granted approval to Vabysmo (faricimab) 6mg single-dose prefilled syringe (PFS) for treating neovascular or ‘wet’ age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). US availability is anticipated in the upcoming months
- Vabysmo’s approval was based on studies showing improved visions and retinal drying in nAMD, DME and RVO. Other worldwide health authority reviews are underway
- Vabysmo, the first bispecific antibody for the eye, targets and inhibits Ang-2 and VEGF-A, pathways linked to vision loss due to destabilization of blood vessels that results in leaky vessels & increased inflammation
Ref: Roche | Image: Roche
Related News:- Roche Reports the CHMP’s Positive Opinion of Vabysmo for Retinal Vein Occlusion (RVO)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
